新京报贝壳财经讯 7月29日，神州细胞公告，其控股子公司神州细胞工程有限公司收到国家药品监督管 理局关于其自主研发产品SCT640C注射液的药物临床试验批准通知书，允许开展成人类风湿关节炎适应 症的临床试验。 ...

Core Viewpoint - Shenzhou Cell's subsidiary has received approval for clinical trials of SCT640C injection for adult rheumatoid arthritis, indicating progress in the development of treatments for autoimmune diseases [1] Group 1 - Shenzhou Cell announced that its subsidiary, Shenzhou Cell Engineering Co., Ltd., has received the Drug Clinical Trial Approval Notice from the National Medical Products Administration [1] - SCT640C is a monoclonal antibody injection independently developed by the company for the treatment of autoimmune diseases [1]